Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ianalumab in Diffuse Cutaneous Systemic Sclerosis (Japan)
jRCT2031250272Recruiting
- Sponsor
- Novartis
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial in diffuse cutaneous systemic sclerosis (dcSSc) comparing Ianalumab → open-label ianalumab with Placebo → open-label ianalumab (2 arms). Primary endpoint: 3/5 rCRISS25 response at Week 52. Started Oct 2025; status: recruiting.
02
Drugs
ianalumab
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on jRCT2031250272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250272.